Free Trial

Structure Therapeutics (GPCR) Competitors

Structure Therapeutics logo
$20.44 -0.07 (-0.34%)
Closing price 04:00 PM Eastern
Extended Trading
$20.74 +0.31 (+1.49%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GPCR vs. AXSM, AKRO, PCVX, ADMA, PTCT, RYTM, CYTK, KRYS, ZLAB, and ACAD

Should you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Zai Lab (ZLAB), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.

Structure Therapeutics vs. Its Competitors

Structure Therapeutics (NASDAQ:GPCR) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Structure Therapeutics has a beta of -1.87, indicating that its share price is 287% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Structure Therapeutics currently has a consensus target price of $76.17, suggesting a potential upside of 272.64%. Axsome Therapeutics has a consensus target price of $172.33, suggesting a potential upside of 65.85%. Given Structure Therapeutics' higher probable upside, equities analysts clearly believe Structure Therapeutics is more favorable than Axsome Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Structure Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Axsome Therapeutics
0 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
3.06

Structure Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Structure TherapeuticsN/AN/A-$122.53M-$0.87-23.49
Axsome Therapeutics$385.69M13.27-$287.22M-$5.77-18.01

Structure Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -64.39%. Structure Therapeutics' return on equity of -16.35% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Structure TherapeuticsN/A -16.35% -15.71%
Axsome Therapeutics -64.39%-272.80%-36.69%

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 9.4% of Structure Therapeutics shares are held by insiders. Comparatively, 22.3% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Axsome Therapeutics had 4 more articles in the media than Structure Therapeutics. MarketBeat recorded 5 mentions for Axsome Therapeutics and 1 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.98 beat Axsome Therapeutics' score of 0.80 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Structure Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Axsome Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Structure Therapeutics and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Structure Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GPCR vs. The Competition

MetricStructure TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.18B$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio-23.4921.3126.1719.90
Price / SalesN/A278.47414.67113.66
Price / CashN/A41.4736.1356.90
Price / Book1.357.518.055.38
Net Income-$122.53M-$55.05M$3.15B$248.50M
7 Day Performance-6.20%2.45%1.85%2.97%
1 Month Performance-6.20%7.33%4.81%6.02%
1 Year Performance-47.22%5.38%34.86%20.39%

Structure Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GPCR
Structure Therapeutics
2.7017 of 5 stars
$20.44
-0.3%
$76.17
+272.6%
-48.7%$1.18BN/A-23.49136
AXSM
Axsome Therapeutics
4.6769 of 5 stars
$101.65
+1.0%
$172.33
+69.5%
+27.1%$4.96B$385.69M-17.62380Analyst Revision
AKRO
Akero Therapeutics
3.6224 of 5 stars
$54.03
-0.3%
$82.50
+52.7%
+122.0%$4.32BN/A-27.7130
PCVX
Vaxcyte
1.7866 of 5 stars
$33.25
+1.2%
$136.50
+310.5%
-57.2%$4.24BN/A-8.33160News Coverage
Positive News
ADMA
ADMA Biologics
4.0975 of 5 stars
$17.87
+0.7%
$27.67
+54.8%
+54.8%$4.24B$426.45M21.02530
PTCT
PTC Therapeutics
4.3298 of 5 stars
$49.60
-1.2%
$65.00
+31.0%
+55.9%$3.98B$806.78M7.621,410Analyst Revision
RYTM
Rhythm Pharmaceuticals
3.7939 of 5 stars
$62.13
+0.2%
$76.62
+23.3%
+53.4%$3.94B$130.13M-22.11140
CYTK
Cytokinetics
4.2861 of 5 stars
$32.64
+0.6%
$70.92
+117.3%
-38.5%$3.87B$19.22M-6.17250Positive News
KRYS
Krystal Biotech
4.6224 of 5 stars
$137.92
+4.1%
$211.13
+53.1%
-23.7%$3.83B$290.52M33.15210Analyst Revision
High Trading Volume
ZLAB
Zai Lab
3.3948 of 5 stars
$36.01
+4.2%
$47.37
+31.5%
+103.4%$3.81B$398.99M-14.461,869Positive News
Analyst Forecast
Insider Trade
Analyst Revision
Gap Up
ACAD
ACADIA Pharmaceuticals
4.6939 of 5 stars
$22.48
-1.0%
$27.64
+23.0%
+33.2%$3.80B$957.80M16.41510

Related Companies and Tools


This page (NASDAQ:GPCR) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners